NewAmsterdam Pharma (NASDAQ: NAMS) grants director RSUs and options

Rhea-AI Filing Summary

NewAmsterdam Pharma Co. N.V. reported that director Mark C. McKenna received new equity awards. On January 7, 2026, he was granted 3,400 restricted stock units (RSUs), each representing the right to receive one ordinary share. These RSUs will vest in full on the one-year anniversary of the vesting start date, conditioned on his continued service. They were granted for no cash consideration, and following this award he beneficially owns 10,360 ordinary shares directly.

On the same date, McKenna also received an option to acquire 15,300 ordinary shares at an exercise price of $35.45 per share, expiring on January 7, 2036. All shares underlying this option will vest on January 2, 2027, also subject to his continued service, leaving him with 15,300 derivative securities beneficially owned.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider McKenna Mark C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	15,300	$0.00	--
Grant/Award	Ordinary Shares	3,400	$0.00	--

Holdings After Transaction: Option (right to buy) — 15,300 shares (Direct); Ordinary Shares — 10,360 shares (Direct)

Footnotes (1)

1. Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. Each RSU was granted on January 7, 2026 for no consideration. All the shares underlying the option will vest on January 2, 2027, the one-year anniversary of vesting start date, subject to the Reporting Person's continued service through such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKenna Mark C.

(Last) (First) (Middle)

C/O NEWAMSTERDAM PHARMA COMPANY N.V.

GOOIMEER 2-35

(Street)

NAARDEN P7 1411 DC

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	01/07/2026		A		3,400(1)	A	(2)	10,360	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$35.45	01/07/2026		A		15,300		(3)	01/07/2036	Ordinary Shares	15,300	$0.00	15,300	D

Explanation of Responses:

1. Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

2. Each RSU was granted on January 7, 2026 for no consideration.

3. All the shares underlying the option will vest on January 2, 2027, the one-year anniversary of vesting start date, subject to the Reporting Person's continued service through such date.

	/s/ Louise Kooij by Power of Attorney from Mark C. McKenna	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does NewAmsterdam Pharma (NAMS) Form 4 report for Mark C. McKenna?

The Form 4 reports that director Mark C. McKenna received new equity awards on January 7, 2026, including 3,400 RSUs and an option over 15,300 ordinary shares, all held directly.

How many restricted stock units did Mark C. McKenna receive from NAMS?

He received 3,400 restricted stock units (RSUs), each representing a contingent right to receive one ordinary share of NewAmsterdam Pharma.

What are the vesting terms of the RSUs granted to the NAMS director?

All 3,400 RSUs will vest on the one-year anniversary of the vesting start date, subject to Mark C. McKenna’s continued service through that date.

What stock options were granted to Mark C. McKenna by NewAmsterdam Pharma?

He was granted an option to buy 15,300 ordinary shares at an exercise price of $35.45 per share, expiring on January 7, 2036.

When do the stock options for 15,300 NAMS shares vest?

All shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, contingent on his continued service.

How many NewAmsterdam Pharma ordinary shares does McKenna own after this Form 4 transaction?

Following the reported RSU grant, Mark C. McKenna beneficially owns 10,360 ordinary shares directly, plus 15,300 derivative securities (stock options).